R&D spending and sources of funding of private US biopharmaceutical firms seeking to go public

Author： Williams David R   Pouder Richard W  

Publisher： Palgrave Macmillan Ltd

ISSN： 1478-565X

Source： Journal of Commercial Biotechnology, Vol.16, Iss.4, 2010-10, pp. : 284-292

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Fixing the paradigm for biopharmaceutical R&D: Where to start?

By Milne Christopher-Paul  

International Journal of Biotechnology, Vol. 10, Iss. 5, 2008-11 ,pp. : 404-415

Inderscience Publishers

Access to resources Recommend Favorite

Impact of the life sciences on organisation and management of R&D in large pharmaceutical firms

By Mittra James  

International Journal of Biotechnology, Vol. 10, Iss. 5, 2008-11 ,pp. : 416-440

Inderscience Publishers

Access to resources Recommend Favorite

Competitive biomedical R&D?

By Sussman P.N.  

Trends in Biotechnology, Vol. 16, Iss. 12, 1998-12 ,pp. : 528-528

Elsevier

Access to resources Recommend Favorite

Technical and efficiency growth rates of biopharmaceutical firms in China

By Lee Yao-Chun   Hsu Yu-Hsueh   Chen Jaw-Ming  

International Journal of Biotechnology, Vol. 9, Iss. 6, 2007-11 ,pp. : 586-606

Inderscience Publishers

Access to resources Recommend Favorite

Will genomics revolutionise pharmaceutical R&D?

By Noble D.  

Trends in Biotechnology, Vol. 21, Iss. 8, 2003-08 ,pp. : 333-337

Elsevier

Access to resources Recommend Favorite